NASDAQ · Financial Statements

OKYO Pharma Limited (OKYO) Revenue, Earnings & Financial Statements

$1.11 NASDAQ: OKYO Market Cap $57.99M

Data as of Nov 17, 2026 close · Statements through the quarter ended Mar 2026 · Source: Financial Modeling Prep (methodology)

OKYO Pharma Limited most recently reported annual revenue of 0, a net loss of 9.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

OKYO Pharma Limited: net profit was positive in 0 of 10 reported years; the most recent year shows a net loss of 9.0M.

Income Statement — 10 Years (millions, reporting currency)

Metric2017201820192020202120222023202420252026
Revenue0000000000
Operating Expenses028.0M5.0M2.0M4.0M6.0M13.0M16.0M7.0M8.0M
Operating Profit0−28.0M−5.0M−2.0M−4.0M−6.0M−13.0M−16.0M−7.0M−8.0M
Other Income00001.0M00−1.0M−1.0M0
Interest00000001.0M1.0M0
Depreciation01.0M00000000
Profit Before Tax0−28.0M−5.0M−2.0M−3.0M−6.0M−13.0M−17.0M−8.0M−9.0M
Tax rate (%)0.0%0.0%0.0%4.7%0.7%12.7%0.1%-0.1%41.0%-0.1%
Net Profit0−28.0M−5.0M−2.0M−3.0M−5.0M−13.0M−17.0M−5.0M−9.0M
EPS−0.04−4.80−0.62−0.17−0.32−0.36−0.600.00−0.12−0.24

Quarterly Results — Last 12 Quarters (millions, reporting currency)

8 duplicate period labels in the source data were collapsed.

MetricSep '20Mar '21Sep '21Mar '22Sep '22Mar '23Sep '23Mar '24Sep '24Mar '25Sep '25Mar '26
Revenue000000000000
Operating Expenses1.0M3.0M3.0M7.0M6.0M09.0M03.0M4.0M3.0M6.0M
Operating Profit−1.0M−3.0M−3.0M−7.0M−6.0M0−9.0M0−3.0M−4.0M−3.0M−6.0M
Interest000000001.0M000
Profit Before Tax−1.0M−3.0M−3.0M−7.0M−6.0M0−9.0M0−4.0M−4.0M−3.0M−6.0M
Tax rate (%)-0.0%0.9%6.9%17.0%0.0%0.2%-0.9%-0.8%34.6%47.7%0.0%-0.1%
Net Profit−1.0M−3.0M−3.0M−6.0M−6.0M0−9.0M0−3.0M−2.0M−3.0M−6.0M
EPS−0.11−0.270.00−0.360.000.000.000.00−0.08−0.04−0.07−0.17

Over the 10 years reported for OKYO Pharma Limited, cash stood at 15.0M in the latest year, shareholders' equity was 174.0M, current assets covered current liabilities 2.33 times.

Balance Sheet — 10 Years (millions, reporting currency)

Metric2017201820192020202120222023202420252026
Total Assets001.0M1.0M7.0M4.0M5.0M2.0M4.0M21.0M
Current Assets17.0M01.0M1.0M7.0M4.0M5.0M2.0M4.0M21.0M
Cash001.0M07.0M3.0M4.0M1.0M2.0M15.0M
Inventory0000000000
Receivables000001.0M1.0M1.0M2.0M0
Fixed Assets0000000000
Capital Work in Progress0000000000
Investments17.0M000000006.0M
Other Assets0000000000
Total Liabilities0001.0M2.0M1.0M7.0M7.0M9.0M9.0M
Current Liabilities0001.0M2.0M1.0M7.0M7.0M9.0M9.0M
Borrowings0000002.0M000
Other Liabilities0001.0M2.0M1.0M5.0M7.0M9.0M9.0M
Equity0089.0M00124.0M000174.0M
Reserves00005.0M3.0M−2.0M−6.0M−6.0M12.0M

For OKYO Pharma Limited, operating cash flow was positive in 0 of 10 reported years; free cash flow in the latest year was negative at 6.0M; free cash flow was positive in 0 of 10 years.

Cash Flow Statement — 10 Years (millions, reporting currency)

Metric2017201820192020202120222023202420252026
Operating Cash Flow−1.0M−2.0M−2.0M−1.0M−2.0M−5.0M−8.0M−9.0M−2.0M−6.0M
Investing Cash Flow−1.0M00000000−6.0M
Financing Cash Flow0001.0M01.0M0000
Net Cash Flow−1.0M−2.0M−2.0M07.0M−4.0M1.0M−3.0M1.0M13.0M
Free Cash Flow−1.0M−2.0M−2.0M−1.0M−2.0M−5.0M−8.0M−9.0M−2.0M−6.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.05
EV / EBITDA-6.57
FCF Yield-7.92%
Quick Ratio2.43
Interest Coverage-20.81
Return 1Y-43.51%
Return 3Y-20.59%
Return 5Y—

OKYO Pharma Limited (OKYO) financials — frequently asked questions

What is OKYO Pharma Limited's annual revenue?

OKYO Pharma Limited (OKYO) reported annual revenue of 0 in its most recent fiscal year.

What is OKYO Pharma Limited's net profit?

OKYO Pharma Limited (OKYO) reported a net loss of 9.0M in its most recent fiscal year.

What is OKYO EV/EBITDA?

OKYO Pharma Limited's enterprise value to EBITDA (EV/EBITDA) ratio is -6.57. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Revenue and earnings of other Biotechnology stocks

VRTX revenue $12.1BREGN revenue $14.3BMRNA revenue $1.9BRVMD financialsROIV revenue $8.0MINSM revenue $606.0MUTHR revenue $3.2BINCY revenue $5.1BALNY revenue $3.7BASND revenue $692.0MAll Biotechnology stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
OKYO Overview OKYO Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.